Showing 2881-2890 of 4063 results for "".
- Alcon to Showcase New Products, Commitment to ECP Education at 2018 Optometry’s Meetinghttps://modernod.com/news/alcon-to-showcase-new-products-commitment-to-ecp-education-at-2018-optometrys-meeting/2480083/Alcon will introduce new products and educational resources to eye care professional (ECP) and paraoptometric audiences at this year’s American Optometric Association (AOA) Optometry’s Meeting taking place June 20-24 in Denver. Notably, Leatrice Eiseman, executive director at the Pantone C
- “Dr. Robert Ritch Forum on Medicine of the Future” at World Ophthalmology Congress 2018https://modernod.com/news/dr-robert-ritch-forum-on-medicine-of-the-future-at-world-ophthalmology-congress-2018/2480090/Robert Ritch, MD, Distinguished Chair in Ophthalmology at New York Eye and Ear Infirmary of Mount Sinai will host the “Robert Ritch Forum on Medicine of the Future” at the World Ophthalmology Congress 2018 (WOC2018) in Barcelona, Spain. This is the first time WOC is dedicating an entire fo
- HelpMeSee Eye Surgery Simulator Demonstrations Scheduled for the 2018 World Ophthalmology Conference in Barcelonahttps://modernod.com/news/helpmesee-eye-surgery-simulator-demonstrations-scheduled-for-the-2018-world-ophthalmology-conference-in-barcelona/2480099/HelpMeSee is presenting their Eye Surgery Simulator and companion eBook for teaching manual small incision cataract surgery (MSICS) at the International Council of Ophthalmology’s (ICO) 2018 World Ophthalmology Conference (WOC) in Barcelona, Spain. WOC attendees interested in scheduling dem
- CMS Issues Preliminary Decision on Unique J Code for Avedro Photrexa Drug Formulationshttps://modernod.com/news/cms-issues-preliminary-decision-on-unique-j-code-for-avedro-photrexa-drug-formulations/2480101/Avedro announced that the Centers for Medicare and Medicaid Services (CMS) has issued a preliminary decision to establish a product specific Healthcare Common Procedure Coding System (HCPCS) J code for Photrexa drug formulations. Claims submitted with a product specific J code are generally proce
- ReGenTree Presents Results of a Comparison Study of RGN-259 and Approved Prescription Drugs for Dry Eyehttps://modernod.com/news/regentree-presents-results-of-a-comparison-study-of-rgn-259-and-approved-prescription-drugs-for-dry-eye-syndrome-in-a-mouse-model-at-arvo/2480176/ReGenTree announced that the company presented results of a comparison study of RGN-259 and marketed products for dry eye syndrome in a dry eye mouse model at the ARVO meeting. The study was conducted by Jaewook Yan
- Ocugen Presents Preclinical Efficacy Data of its Proprietary Nanoemulsion Technology at ARVO 2018https://modernod.com/news/ocugen-presents-preclinical-efficacy-data-of-its-proprietary-nanoemulsion-technology-at-arvo-2018/2480184/Ocugen announced that it presented additional preclinical findings in a poster highlighting the potential efficacy of its unique, patented nanoemulsion formulation of brimonidine tartrate (OCU300) at the Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting, held
- ReGenTree Presents Results of a Comparison Study of RGN-259 and Approved Prescription Drugs for Dry Eye Syndromehttps://modernod.com/news/regentree-presents-results-of-a-comparison-study-of-rgn-259-and-approved-prescription-drugs-for-dry-eye-syndrome/2480185/ReGenTree, a joint venture between GtreeBNT and RegeneRx Biopharmaceuticals, announced that the company presented results of a comparison study of RGN-259 and marketed products for dry eye syndrome in a dry eye mouse model at ARVO (The Association for Research in Vision and Ophthalmology)
- Avedro Announces $25 Million in Funding to Fuel Innovation and Commercial Growthhttps://modernod.com/news/avedro-announces-25-million-in-funding-to-fuel-innovation-and-commercial-growth/2480188/Avedro announced that it has secured $25 million in financing to invest in product development, clinical studies and commercial efforts, including expansion of sales and reimbursement support. “Avedro’s mission is to develop noninvasive corneal remodeling treatments that protect and improv
- Aldeyra Therapeutics Presents Dry Eye Disease Phase 2a Clinical Trial Results at ARVOhttps://modernod.com/news/aldeyra-therapeutics-presents-dry-eye-disease-phase-2a-clinical-trial-results-at-arvo/2480191/Aldeyra Therapeutics presented the results of a randomized, double-masked, parallel-group phase 2a dry eye disease clinical trial of topical ocular reproxalap at the Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting. The primary objective of the trial, to select a fo
- Call for Abstracts for Academy 2018 San Antonio Scientific Programhttps://modernod.com/news/call-for-abstracts-for-academy-2018-san-antonio-scientific-program/2480193/The Scientific Program Committee of the American Academy of Optometry invites the submission of abstracts for Academy 2018 San Antonio, to be held Wednesday, November 7 through Saturday, November 10. The Academy’s Scientific Program offers scientists, educators, and clinicians the opportuni